Jardiance (empagliflozin Tablets)

Jardiance (Empagliflozin Tablets) - Product Information

Jardiance (Empagliflozin tablets) is used along with diet and exercise for treatment of type 2 diabetes mellitus to improve glycaemic control in certain patients.

Jardiance tablets are manufactured by Boehringer Ingelheim, Germany in the strengths of 10 mg and 25 mg. We also have in stock Generic Actos (Pioglitazone Tablets) which is also used to treat type 2 diabetes mellitus.

Name of the Drug

We supply original Jardiance tablets manufactured by Boehringer Ingelheim in Germany.

Manufacturer of Jardiance Tablets

  Boehringer Ingelheim, Germany
Website: www.boehringer-ingelheim.com

Active Ingredient present in Jardiance Tablets

The active ingredient present in Jardiance tablets is Empagliflozin. Each Jardiance tablet contains 10 mg or 25 mg of Empagliflozin.

Uses of Jardiance Tablets

Jardiance Tablets are used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

This diabetes medicine is used in adults as monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of Metformin HCl tablets (Glycomet) is not considered appropriate due to intolerance as well as add-on combination therapy with other glucose –lowering medicinal products including insulin when these together with diet and exercise do not provide adequate glycaemic control.

Administering Empaglifozin to patients with type 2 diabetes reduces the risk of death from cardiovascular disease in those with a previous history of cardiovascular disease.

Jardiance (Empagliflozin Tablets) - Dosage

The recommended oral dose of Jardiance (Empagliflozin Tablets) is 10 mg once daily, administered in the morning, with or without food. The dose may be increased to 25 mg once daily.

Renal function must be assesed before starting treatment with Jardiance Tablets. Treatment with Jardiance tablets should not be started if eGFR is below 45 mL/min/1.73 m2 and must be discontinued if eGFR falls below 45 mL/min/1.73 m2.

Jardiance Tablets - Storage Instructions

Store Jardiance tablets at controlled room temperature ( 68°F to 77°F, 20°C to 25°C). Protect from light.

Jardiance Tablets - Contraindications

Jardiance tablets are contraindicated in patients with a hypersensitivity to Empagliflozin or any inactive ingredient present in Jardiance tablets.
This medication is also contraindicated in patients with type 1 diabetes, high blood or urine ketone levels (diabetic ketoacidosis), Severe renal impairment, end-stage renal disease, or dialysis.

Jardiance Side Effects

The very common side effect of Jardiance (Empagliflozin Tablets) is Hypoglycaemia (when used with sulphonylurea or insulin). The common Empagliflozin side effects include Vaginal moniliasis, vulvovaginitis, balanitis and other genital infections, Urinary tract infection, Thirst, Pruritus (generalised), Increased urination and Serum lipids increased.

Uncommon side effects include Volume depletion, Dysuria, Blood creatinine increased/Glomerular filtration rate decreased and Haematocrit increased. Rare side effect ocurring in less than 1 in thousand patients is Diabetic ketoacidosis. Stop taking Jardiance and call your doctor immediately in case you get any of the following symptoms:

• nausea
• tiredness
• vomiting
• trouble breathing
• stomach-area (abdominal) pain

If you get any of these symptoms during treatment with Empagliflozin tablets, check for ketones in your urine if possible, even if your blood sugar is less than 250 mg/dL.

Warnings and Precautions

Before starting treatment with Jardiance (Empagliflozin Tablets) patients have to be assessed and volume status corrected in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics. Patients must be monitored for signs and symptoms of hypotension during treatment.

Assess patients who show signs and symptoms of metabolic acidosis for ketoacidosis must be assesed regardless of blood glucose level. If suspected, discontinue Jardiance, evaluate and treat promptly.

Before starting Jardiance therapy, consider risk factors for ketoacidosis. Patients on may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis.

In cases of acute kidney injury and impairment in renal function, the doctor should consider temporarily discontinuing in settings of reduced oral intake or fluid losses. In case acute kidney injury occurs, discontinue Jardiance and treat immediately. Renal function should be monitored during treatment.

Evaluate patients for signs and symptoms of urinary tract infections and treat immediately, if indicated.

Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia when starting treatment with Jardiance. In case of genital mycotic infections, monitor and treat as necessary.

Monitor and treat increased LDL-C as appropriately.

Studies on the effects on the ability to drive and use machines have not been performed.

Urine will test positive for glucose while patients are taking Jardiance tablets due to the nature of the mechanism of action of the SGLT2 inhibitors.

The safety and effectiveness of this medicine in pediatric patients under 18 years of age have not been established.

Overdosage

In case of Jardiance overdose the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as necessary due to the patient’s clinical status. Removal of Empagliflozin by hemodialysis has not been studied.

Empagliflozin During Pregnancy

Empagliflozin Tablets (Jardiance by Boehringer Ingelheim) has been classified by the US FDA as Pregnancy Category C. Animal studies have shown evidence that this medicine crosses the placenta and reaches fetal tissues, possibly affecting renal development and maturation. At maternally toxic doses, malformation of limb bones and increased embryofetal loss were observed. There are no controlled data in human pregnancy.

Animal data has revealed adverse renal effects with administration of this medicine during the renal development period which corresponds to the late second and third trimesters of human pregnancy.

Do not use this medicine without your doctor's consent in case you are pregnant. Stop using this medication and inform your doctor immediately if you become pregnant during treatment.

Empagliflozin Tablets - Nursing Considerations

Use of Empagliflozin Tablets (Jardiance by Boehringer Ingelheim) is not recommended by nursing mothers and a decision should be made to discontinue breastfeeding or discontinue Jardiance, taking into account the importance of the medication to the mother. While it is not known if Empagliflozin is excreted into human milk, there is potential for serious harm to the developing kidney in case the breastfed infant is exposed. Human kidney maturation occurs in utero during the first 2 years of life.
Do not use this medication without telling your doctor if you are breast-feeding a baby.

Buy Jardiance 10mg Pills Online at Only $2.31 per Pill

You can buy Empagliflozin tablets online from Clear Sky Pharmacy at a cheap price. Jardiance 10 mg and 25 mg pills, manufactured by Boehringer Ingelheim, Germany are supplied in a blister strip of 10 tablets. The 10mg tablets cost only $2.31 per unit when you place an order for 320 tablets.

Disclaimer

The above information is provided to the best of our knowledge and in good faith, it is without a warrant of any kind, expressed or implied.

Shipping Restriction